MapLight Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
MapLight Therapeutics, Inc. carries a market capitalization of 20.99M, placing it among publicly traded companies globally. Its enterprise value stands at 500.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 20.99M |
| Enterprise Value | 500.46M |
Share Statistics
MapLight Therapeutics, Inc. currently has 45.21M shares outstanding.
| Shares Outstanding | 45.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.91 |
| P/TBV Ratio | 2.01 |
| P/FCF Ratio | -6.22 |
| P/OCF Ratio | -6.20 |
Financial Position
MapLight Therapeutics, Inc. maintains a current ratio of 22.91, meaning it holds 22.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 22.91 |
| Quick Ratio | 21.71 |
| Debt / Equity | 1.40 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -180.36 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
MapLight Therapeutics, Inc.'s stock has gained approximately 44.99564% over the past 52 weeks. The 50-day moving average sits at 26.87, while the 200-day moving average is 20.51.
| Beta (5Y) | N/A |
| 52-Week Price Change | 44.99564% |
| 50-Day Moving Average | 26.87 |
| 200-Day Moving Average | 20.51 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -178.94M, while operating income came in at -179.38M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -179.38M |
| Pretax Income | -169.63M |
| Net Income | -169.63M |
| EBITDA | -178.94M |
| EBIT | -179.38M |
| Earnings Per Share (EPS) | -4.28 |
Balance Sheet
MapLight Therapeutics, Inc. holds 310.11M in cash and equivalents against 5.59M in total debt, resulting in a net debt position of -55.71M. Total book value stands at -421.18M, with working capital of 312.95M providing operational flexibility.
| Cash & Cash Equivalents | 310.11M |
| Total Debt | 5.59M |
| Net Debt | -55.71M |
| Equity (Book Value) | -421.18M |
| Book Value Per Share | -10.64 |
| Working Capital | 312.95M |
Cash Flow
MapLight Therapeutics, Inc. produced -129.80M in operating cash flow over the past twelve months. After subtracting -431,000.00 in capital expenditures, free cash flow totaled -130.23M - equivalent to -3.29 per share.
| Operating Cash Flow | -129.80M |
| Capital Expenditures | -431,000.00 |
| Free Cash Flow | -130.23M |
| FCF Per Share | -3.29 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -57.54 |
| FCF Yield | -16.07 |
Scores
MapLight Therapeutics, Inc. posts an Altman Z-Score of 23.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 23.56 |